Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis
Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis
复制标题
DOI：
10.1016/j.amjmed.2004.03.044
复制
发表时间：
2005-01-01
影响因子：
5.9
通讯作者：
Rose, DN
中科院分区：
文献类型：
--
作者：
Rothberg, MB;Rose, DN
目的：确定流感疫苗接种、抗病毒治疗或不干预对健康工作成年人的成本效益，考虑疫苗疗效的年度变化。方法：我们根据已发表的流感疫苗和抗病毒药物的临床试验进行了成本-效果分析，并结合了世界卫生组织流感样疾病10年的监测数据。我们以普通社区或工作场所50岁以下的健康工作成年人为目标，对流感疫苗接种、治疗药物或两者都进行了建模，与不进行干预的情况进行了比较。结果包括费用、患病天数和质量调整天数。结论：健康成人接种流感疫苗在经济上是合理的，在一定情况下是节约成本的。抗病毒治疗一直在节省费用。(C) 2005爱思唯尔公司版权所有。
Purpose: To determine the cost-effectiveness of influenza vaccination, antiviral therapy, or no intervention for healthy working adults accounting for annual variation in vaccine efficacy.Methods: We conducted a cost-effectiveness analysis based on published clinical trials of influenza vaccine and antiviral drugs, incorporating 10 years of surveillance data from the World Health nt of influenza-like illness with antiviral Organization. We modeled influenza vaccination, treatments drugs, or both, as compared with no intervention, targeting healthy working adults under age 50 years in the general community or workplace. Outcomes included costs, illness days, and quality-adjusted days (.) gained.Conclusion: Influenza vaccination for healthy working adults is reasonable economically, and under certain circumstances is cost saving. Antiviral therapy is consistently cost saving. (C) 2005 Elsevier Inc. All rights reserved.